Table 1.
Baseline characteristics of patients in the present study.
| All patients, n = 185 |
Patients with dual therapy, n = 146 | Patients with triple therapy, n = 39 | P values (dual therapy versus triple therapy groups) | |
|---|---|---|---|---|
| Gender, male/female | 102/83 | 73/73 | 29/10 | 0.011 |
| Age, years | 56.2 ± 10.7 | 55.7 ± 11.2 | 58.2 ± 8.7 | 0.197 |
| Previous treatment: naïve/relapse/null | 119/45/21 | 102/26/18 | 17/19/3 | 0.0043 (naïve versus non-naïve) |
| AST, IU/L | 57.1 ± 48.0 | 58.0 ± 48.7 | 53.9 ± 45.9 | 0.630 |
| ALT, IU/L | 70.4 ± 64.7 | 71.0 ± 64.9 | 68.1 ± 64.8 | 0.800 |
| γ-GTP, IU/L | 57.0 ± 66.7 | 56.4 ± 68.6 | 59.2 ± 59.8 | 0.816 |
| Hemoglobin, g/dL | 14.1 ± 1.3 | 14.0 ± 1.2 | 14.6 ± 1.3 | 0.0070 |
| Platelets, ×104/mm3 | 16.6 ± 5.6 | 16.8 ± 5.8 | 16.0 ± 5.1 | 0.434 |
| Treatment response | ||||
| RVR, n | 42 | 15 | 27 | <0.0001 |
| EVR, n | 99 | 65 | 34 | <0.0001 |
| SVR/relapse/null | 104/39/42 | 72/37/37 | 32/2/5 | <0.0001 |
| IFNL4, ss469415590, major/minor/ND |
117/61/7 | 93/48/5 | 24/13/2 | 0.944 |
Peginterferon plus ribavirin with or without telaprevir therapy was defined as triple or dual therapy, respectively. Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.